CytRx announces Phase II trial of bafetinib in CRPC


Bafetinib (previously known as INNO-406) is a protein kinase inhibitor that targets two different enzymes. The newly announced trial is designed to investigate the potential of bafetinib in the treatment of men with castration-resistant prostate cancer (CRPC) who have progressive disease after treatment with at least one course of chemotherapy.

The Phase II PROstate Advanced Cancer Treatment (PROACT) trial is being conducted at the City of Hope cancer center, outside of Los Angeles, California, as well as in several centers in India. For details about this trial and more information about bafetinib, readers can read the media release from CytRx Corp. There seems to be no listing of this trial on the ClinicalTrials.gov web site at the present time.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: